Autolus Raises $80m To Take T-Cell Engineering To The Next Level
Three-year-old clinical-stage UK biotech Autolus will use its $80m (£59m) Series C financing to advance three dual targeting CAR-T candidates in the clinic and build capacity.
Three-year-old clinical-stage UK biotech Autolus will use its $80m (£59m) Series C financing to advance three dual targeting CAR-T candidates in the clinic and build capacity.